LONDON, Oct 22 (Reuters) – GlaxoSmithKline, battered
by weak U.S. drug sales and a bribery scandal in China, set out
a bold recovery plan on Wednesday, including an initial public
offering of part of its fast-growing HIV and AIDS drugs
As a standalone company ViiV Healthcare would be among the
top 40 companies in London’s FTSE 100 index, outranking such
household names as retailer Marks and Spencer, GSK Chief
Executive Andrew Witty told reporters.
LONDON (Reuters) – Leading drugmakers plan to work together to accelerate development of an Ebola vaccine and produce millions of doses of the most effective experimental product for use next year.
Johnson & Johnson (JNJ.N: Quote, Profile, Research) said on Wednesday that it aims to produce at least 1 million doses of its two-step vaccine next year and has already discussed collaboration with Britain’s GlaxoSmithKline (GSK.L: Quote, Profile, Research), which is working on a rival vaccine.
LONDON (Reuters) – Johnson & Johnson is accelerating work on its experimental Ebola vaccine and said on Wednesday that it aims to have 1 million doses ready in 2015, of which 250,000 are expected to be available by May.
There is currently no proven vaccine against the deadly disease but several companies are racing to develop products and clinical tests on two – from GlaxoSmithKline and NewLink Genetics – are already under way.